T
he New England Journal of Medicine (NEJM) recently opened a debate about the management of physician-industry relationships when its editor in chief, Jeffrey Drazen, questioned whether the divide between academia and industry is in the public's best interest (1) . In a series of commentaries, Lisa Rosenbaum, a NEJM national correspondent, questioned whether zealous policies that prohibit people with industry relationships from publishing journal articles really protect patients or merely cloak an anti-industry bias in false scientific virtue (2) (3) (4) . Countering those views, authors of a feature essay in the British Medical Journal (BMJ) (all previously employed by NEJM) and BMJ editors condemned the suggestion that journals reconsider policies that preclude researchers with industry relationships from writing articles (5, 6). As editors ourselves, we walk this tightrope daily and want to share how we judge and balance these issues.
Some journals have blanket prohibitions against consideration of specific types of papers written by individuals with industry relationships. For example, BMJ implemented a policy in 2014 that prohibits such authors from publishing "educational articles" (5) . Between 1990 and 2002, NEJM precluded anyone who had a financial relationship with industry from writing an editorial (6) . Annals of Internal Medicine does not now nor has it ever had a black-and-white policy banning certain types of authors from publishing articles in the journal. The absence of such a policy does not mean, however, that we ignore these relationships or fail to recognize their potential to introduce bias. As Frank Davidoff, Annals editor from 1995 to 2001, wrote in 1997, we know that industry relationships can be an important source of bias (7). Thus, the potential for financial conflict does contribute to the decision not to publish an article. Consequently, the pages of Annals are not teeming with editorials and review articles written by people with a financial stake in their subject.
Why don't we have blanket proclamations about potential conflicts and authorship? Because we simply believe it is impossible to create strict rules about something that is always a judgment call. We agree with Drs. Drazen and Rosenbaum that the mere presence of a relationship with industry does not necessarily mean that an individual is incapable of writing a responsible piece of work that readers will find useful. Conversely, the absence of such relationships does not ensure that the work is balanced, responsible, and educational. Thus, we make decisions on a case-by-case basis.
An ironclad rule applied only to relationships with the pharmaceutical industry is prejudicial reductionism: It naively oversimplifies and promulgates a false sense of security and purity. Everyone-academics, chief executive officers and employees of pharmaceutical companies, clinicians, editors, patients, and governmentfunded researchers-have biases that shape their perspectives and how they might write or interpret. Responsible discourse in medical science requires that we think critically about all that we read, not just about material written by persons tied to one industry or another.
Annals requires that all authors complete the International Committee of Journal Editors uniform disclosure form, which asks them to disclose relationships that present potential conflicts of interest (8) . When making editorial decisions, we consider those relationships. When we think conflicts are present, we make judgments about how they might affect both the possibility of bias and the credibility of the published paper.
If we publish such a paper, it is because we believe it contains enough information for our readers to make their own judgments, in part because each article is accompanied by links to the actual disclosure forms that each author completed. If readers think that author relationships undermine the article's credibility, they can skip the article altogether, take its conclusions with a grain of salt, post their concerns as a comment, or combine these options.
We prefer writers without industry relationships for editorials and commentaries, except in specific cases when obtaining an industry perspective is specifically our intent (9) . At the other extreme, we never decline to publish a research article simply because an author has industry ties. We avoid narrative reviews that are written solely by authors with industry ties because such reviews provide little information about how the authors searched for, selected, evaluated, and summarized the evidence, which makes it difficult to judge whether the review provides a balanced view of available evidence. High-quality systematic reviews with detailed methods and transparent reporting written by authors with industry ties are never automatically excluded from consideration.
It is common for physicians to work with industry and, although Steinbrook and colleagues imply that the collaboration might not require financial exchange (5), it seems naive to think that academics could (or should) spend time doing work that is not compensated in some manner-either directly to them or indirectly to their institutions. We also think that it is unrealistic to create a sharp divide between evidence generation and its appraisal, as the BMJ editors recommend (5). Good science is iterative, with a constant back and forth between data collection and interpretation.
The elephant in the room that is not addressed in any of the recent commentaries is that BMJ and NEJM, like Annals and all of our parent organizations, sell advertisements and reprints to industry and engage with it in other ways. These activities are very different from the creation of journal content, but if industry can't be This article was published online first at www.annals.org on 14 July 2015.
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EDITORIAL trusted, why engage it in any manner? We sell ads because doing so allows us to provide our readers with better services at lower cost.
We all benefit from health care interventions that would not exist without industry and its collaborators. Rather than treat them as pariahs, we should be grateful to the academics and patients who work with industry to develop and continuously improve these products. Even a "zero tolerance" policy would not guarantee objectivity. With the right checks and balances, we believe that it is possible for us to allow our readers to benefit from the insights that come from some industry relationships. Journals must set guidelines about the disclosure of conflicts and use these disclosures to make responsible editorial decisions. But each and every decision is a delicate balance that weighs expertise against potential conflicts.
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